Literature DB >> 1656972

Glycosylation of high-affinity thrombin receptors appears necessary for thrombin binding.

G H Frost1, J S Bergmann, D H Carney.   

Abstract

Monosaccharide binding competition, lectin affinity chromatography, and glycosylation inhibitors have been used to determine if glycosylation plays a role in thrombin-receptor interactions. Mannose appeared to specifically inhibit thrombin binding to mouse embryo (ME) and hamster fibroblasts. Concanavalin A bound to antibody-purified receptor fractions, and was used as an affinity ligand to purify receptor fractions that retained thrombin binding activity. Cells treated with tunicamycin (6.25 ng/ml) for 24 h lost approximately 35% of their high-affinity thrombin binding sites, yet binding of receptor monoclonal antibody TR-9 was not affected, indicating that the receptor was present in the membrane, but unable to bind thrombin. Thus thrombin receptor glycosylation may be directly involved in thrombin binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656972     DOI: 10.1016/s0006-291x(05)81299-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Functional role for the angiotensin II receptor (AT1A) 3'-untranslated region in determining cellular responses to agonist: evidence for recognition by RNA binding proteins.

Authors:  T J Thekkumkara; W G Thomas; T J Motel; K M Baker
Journal:  Biochem J       Date:  1998-01-15       Impact factor: 3.857

2.  Tunicamycin inhibits prostaglandin F2 alpha receptor-mediated phosphoinositide hydrolysis in cultured rat astrocytes.

Authors:  J Kitanaka; T Hamano; M Gotoh; H Hashimoto; A Baba
Journal:  Neurochem Res       Date:  1994-12       Impact factor: 3.996

3.  Delineation of ligand binding and receptor signaling activities of purified P2Y receptors reconstituted with heterotrimeric G proteins.

Authors:  Erik T Bodor; Gary L Waldo; Rainer Blaesius; T Kendall Harden
Journal:  Purinergic Signal       Date:  2004-12       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.